23 August 2025 - MSD Australia & New Zealand is astonished that after eight years of dialogue and consideration, the PBAC which advises the Federal Government on medicines access has outright rejected a funding proposal that would have removed inequities of access to a cancer treating immunotherapy in Australia.

The company is concerned that this decision will leave some cancer patients bereft of reimbursed treatment options, while foregoing an opportunity to deliver equity of cancer care to thousands of Australians, including those with certain rare cancers.

Read MSD press release